These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 17612006)

  • 1. Lapatinib shows promise for inflammatory breast cancer.
    Cancer Biol Ther; 2007 Jan; 6(1):8. PubMed ID: 17612006
    [No Abstract]   [Full Text] [Related]  

  • 2. Lapatinib-associated toxicity and practical management recommendations.
    Moy B; Goss PE
    Oncologist; 2007 Jul; 12(7):756-65. PubMed ID: 17673607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
    Johnston S; Trudeau M; Kaufman B; Boussen H; Blackwell K; LoRusso P; Lombardi DP; Ben Ahmed S; Citrin DL; DeSilvio ML; Harris J; Westlund RE; Salazar V; Zaks TZ; Spector NL
    J Clin Oncol; 2008 Mar; 26(7):1066-72. PubMed ID: 18212337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lapatinib for inflammatory breast cancer.
    Hall PS; Hanby A; Cameron DA
    Lancet Oncol; 2009 Jun; 10(6):538-9. PubMed ID: 19482243
    [No Abstract]   [Full Text] [Related]  

  • 5. Early success of combined EGFR and Her2 receptor blockade as a clinical strategy in breast cancer.
    Cancer Biol Ther; 2004 Jun; 3(6):490. PubMed ID: 15717407
    [No Abstract]   [Full Text] [Related]  

  • 6. Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer.
    Mukherjee A; Dhadda AS; Shehata M; Chan S
    Expert Opin Pharmacother; 2007 Sep; 8(13):2189-204. PubMed ID: 17714070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lapatinib in breast cancer.
    Bilancia D; Rosati G; Dinota A; Germano D; Romano R; Manzione L
    Ann Oncol; 2007 Jun; 18 Suppl 6():vi26-30. PubMed ID: 17591827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials.
    Tuma RS
    J Natl Cancer Inst; 2007 Mar; 99(5):348-9. PubMed ID: 17341725
    [No Abstract]   [Full Text] [Related]  

  • 9. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lapatinib in the treatment of HER-2 overexpressing breast cancer.
    Vrdoljak E; Boban M; Ban M
    J BUON; 2011; 16(3):393-9. PubMed ID: 22006739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lapatinib ditosylate: expanding therapeutic options for receptor tyrosine-protein kinase erbB-2-positive breast cancer.
    Awada A; Saliba W; Bozovic-Spasojevic I
    Drugs Today (Barc); 2011 May; 47(5):335-45. PubMed ID: 22013564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
    Cameron DA; Stein S
    Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study.
    Kaufman B; Trudeau M; Awada A; Blackwell K; Bachelot T; Salazar V; DeSilvio M; Westlund R; Zaks T; Spector N; Johnston S
    Lancet Oncol; 2009 Jun; 10(6):581-8. PubMed ID: 19394894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel approaches to advanced breast cancer: bevacizumab and lapatinib.
    Mayer EL; Lin NU; Burstein HJ
    J Natl Compr Canc Netw; 2007 Mar; 5(3):314-23. PubMed ID: 17439759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib.
    Burris HA
    Oncologist; 2004; 9 Suppl 3():10-5. PubMed ID: 15163842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lapatinib in metastatic breast cancer.
    Frenel JS; Bourbouloux E; Berton-Rigaud D; Sadot-Lebouvier S; Zanetti A; Campone M
    Womens Health (Lond); 2009 Nov; 5(6):603-12. PubMed ID: 19863462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
    Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
    Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacological profiles and clinical effects of lapatinib tosilate (Tykerb)].
    Arai H; Yamaki M; Nishimura Y
    Nihon Yakurigaku Zasshi; 2010 Sep; 136(3):175-84. PubMed ID: 20838021
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of lapatinib monotherapy on QOL and pain symptoms in patients with HER2+ relapsed or refractory inflammatory breast cancer.
    Kaufman B; Wu Y; Amonkar MM; Sherrill B; Bachelot T; Salazar V; Viens P; Johnston S
    Curr Med Res Opin; 2010 May; 26(5):1065-73. PubMed ID: 20214527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials.
    Xu ZQ; Zhang Y; Li N; Liu PJ; Gao L; Gao X; Tie XJ
    BMJ Open; 2017 Mar; 7(3):e013053. PubMed ID: 28289045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.